Abbott, a player in healthcare, has launched the Navitor Vision in India, offering a new treatment option for patients suffering from symptomatic severe aortic stenosis who are at high or extreme surgical risk. This innovative device is part of Abbott’s Navitor transcatheter aortic valve implantation/replacement (TAVI/TAVR) system.
Enhanced Design for Improved Performance
The Navitor Vision is the latest version of the company’s well-regarded Navitor platform, known for its stability, performance, and readiness for the future. This new iteration features three large Vision markers that enhance visibility and facilitate easier valve deployment during TAVI/TAVR procedures. These markers enable interventionists to implant the device with greater accuracy while ensuring the valve is more visible throughout the procedure.
Addressing the Challenges of Aortic Stenosis
Aortic stenosis is a common and life-threatening heart valve disease. Traditionally, the standard treatment for severe aortic stenosis was surgical aortic valve replacement. However, not all patients are candidates for open-heart surgery due to various health risks.
A Less Invasive Alternative to Open-Heart Surgery
Neeraj Singh is the Country Manager for Abbott’s Structural Heart Business in India. He emphasized the importance of TAVI. TAVI serves as a less invasive alternative for patients at high surgical risk.
He noted that open-heart surgery might be considered too risky for individuals with conditions such as advanced age, frailty, or other underlying diseases. TAVI, on the other hand, offers a safer option that can alleviate symptoms and potentially extend the life expectancy of patients with aortic stenosis.
Versatility and Precision in Treatment
The Navitor Vision valve is available in a range of sizes. These sizes range from 19 mm to 27 mm. This range accommodates nearly all patients who require TAVI.
This flexibility ensures that the device can effectively treat a broad patient population. Additionally, the valve includes a dynamic sealing cuff, which minimizes blood leakage back into the heart, improving overall outcomes.
FlexNav Delivery System for Precise Valve Placement
The Navitor Vision valve is implanted using Abbott innovative FlexNav delivery system. The FlexNav system boasts a slim design, enabling it to treat patients with vessels as small as 5.0 mm. Its versatility allows it to accommodate a range of aortic anatomies, ensuring stable, predictable, and accurate valve delivery and placement.
As reported by biospectrumindia.com, Abbott’s Navitor Vision offers a promising new solution for high-risk aortic stenosis patients, providing both enhanced performance and greater treatment precision. With this launch, Abbott continues to advance its commitment to improving the lives of individuals with structural heart diseases.